Litigation: SEC Charges Biopharmaceutical Company Employee With Insider Trading
September 11, 2024
September 11, 2024
WASHINGTON, Sept. 11 -- The Securities and Exchange Commission issued the following litigation release (No. 1:24-civ-12316; D. Mass filed Sept. 10, 2024) involving Dishant Gupta:
* * *
The Securities and Exchange Commission today charged New Jersey resident Dishant Gupta with insider trading ahead of an announcement that Ipsen Biopharmaceuticals, Inc., Gupta's employer, had agreed to acquire Epizyme, Inc.
According to the SEC's complaint, filed in the U.S. . . .
* * *
The Securities and Exchange Commission today charged New Jersey resident Dishant Gupta with insider trading ahead of an announcement that Ipsen Biopharmaceuticals, Inc., Gupta's employer, had agreed to acquire Epizyme, Inc.
According to the SEC's complaint, filed in the U.S. . . .